Comparing 14-Day Bismuth-Amoxicillin-Vonoprazan Triple Therapy and Bismuth-Based Quadruple Therapy as First-Line Treatments for Helicobacter Pylori Infection

What this Trial Is About

Researchers are evaluating the effectiveness and safety of two different 14-day treatment regimens for adults infected with Helicobacter pylori. The study compares a triple therapy consisting of bismuth, amoxicillin, and vonoprazan to a quadruple therapy including bismuth, rabeprazole, tetracycline, and metronidazole. Additionally, the study aims to understand how antibiotic resistance and specific genetic factors related to the host affect treatment success. Participants will be randomly assigned to one of two groups one receiving the bismuth-amoxicillin-vonoprazan triple therapy and the other receiving the bismuth-based quadruple therapy. Both treatments are taken over 14 days. The triple therapy involves vonoprazan 20 mg twice daily, tripotassium dicitrate bismuthate 300 mg four times daily, and amoxicillin 750 mg four times daily. The quadruple therapy includes rabeprazole 20 mg twice daily, tripotassium dicitrate bismuthate 300 mg four times daily, tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily. During the study, participants will be followed up at 2 weeks to check adherence to treatment and any side effects. At 6 weeks, the Helicobacter pylori infection status will be assessed using a C13-urea breath test. Researchers will compare eradication rates and adverse events between the two groups and analyze how antibiotic resistance and genetic factors influence outcomes. The study involves 552 adults across multiple medical centers and lasts through the treatment and follow-up periods.

Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy